New hope for halting devastating kidney attack

This study tested whether adding a drug called eculizumab to standard treatment could improve outcomes for people with anti-GBM disease, a severe autoimmune condition that rapidly attacks the kidneys. Sixteen adult patients with confirmed disease received the drug, which blocks a part of the immune system thought to drive kidney damage. The main goal was to see if this approach could prevent patients from needing long-term dialysis or a kidney transplant.